Company profile
LGC Limited
LGC Group - LGC Group
LGC Group is a global leader in the life sciences sector; our scientific tools and solutions are essential to our customers goals.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Confirmation Statement With No Updates
Confirmation-statementCS01 | Transaction MzQ0MzcwNzI5NWFkaXF6a2N4
Published 18 Nov 2024 12:20
Accounts With Accounts Type Full
Accounts PDF pendingAA | Transaction MzQ0MjAxMTA1OWFkaXF6a2N4 | Paper/PDF filed
Published 10 Nov 2024 06:41
Termination Secretary Company With Name Termination Date
OfficersTM02 | Transaction MzQzNzcxNDg5OWFkaXF6a2N4
Published 30 Sep 2024 10:53
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Enabling reproducible and scalable AAV production through advanced metabolomic analysis of HEK293 suspension cells
1 Apr 2026 to 30 Jun 2026
This project will pioneer a new approach to making viral vectors --- the essential building blocks for many advanced therapies --- by combining precision small-scale manufacturing with world-class molecular measurement. It brings together BiologIC Technologies, developer of the Qudos personal biomanufacturing system, and the National Measurement Laborator...
A4I - Critical enablers
1 Feb 2026 to 31 Jul 2026
Agroceutical Products Ltd is developing a reliable UK supply of **galanthamine**, a licensed medicine used to treat symptoms of Alzheimer's disease and found naturally in daffodils. Our main research project, **GalanCEAmine**, uses controlled-environment farming and a new extraction process to increase the amount of this valuable molecule we can obtain fr...
SMRT-FIT – characterisation of SupraMolecular RNA Therapeutic formulations to accelerate regulatory path to First-In-human clinical Trials
1 Feb 2026 to 31 Jul 2026
This A4I project will support Innovate-UK funding for development of a novel "**S**upra**M**olecular" **R**NA **T**herapeutic (**SMRT**) delivery system and flexible, scalable RNA-manufacturing process for the sustainable manufacture of biologic drugs. Combined, the material and process will reduce considerably the material-use and energy-costs compared t...
Functionalised Graphene Electrode Biosensor
1 Sep 2024 to 30 Nov 2024
ProMake sets to represent a ground-breaking initiative aimed at revolutionising the landscape of diagnostic technologies through the development and validation of an innovative biosensor technology. This initiative is set to transform the way pathogens, including viruses and bacteria, are detected, making strides towards offering a rapid, sensitive, and c...
Removal of colouration from product
1 Sep 2024 to 28 Feb 2025
**Aqdot**, a young **UK-based** Chemtech company, has completed relevant regulatory approvals and is now accelerating scaling of a novel macrocyclic chemical, **cucurbit\[n\]uril**, "**CB\[n**\]". Cucurbit\[n\]urils are extremely effective "supramolecular hosts": they non-covalently bind a wide range of chemical "guests". Cucurbit\[n\]urils have potential...
Standardised measurements of surface functionalities on nanoparticles
1 Jul 2024 to 30 Jun 2027
Engineered nanoparticles have great application potential in fields such as medicine, sensing, catalysis, energy storage, and opto-electronics. The utility and performance of engineered nanoparticles is largely determined by their surface chemistry. However, documented standards to measure such surface chemistry and functionality do not currently exist. S...
Improvement of microbiome sample processing and analysis using novel testing standards
1 Jun 2024 to 31 Aug 2024
Salient Labs Ltd is a UK-based biomedical diagnostics SME with a focus on microbiome analysis. Microbiomes are integral to an individual's health, and microbiome composition can be used to diagnose or predict the risk of disease. The oral microbiome has been implicated in both dental disease and systemic diseases such as diabetes and cancer. Disease diagn...
Understand and eliminate batch-to-batch variation in solubility of cucurbit[n]uril
1 May 2024 to 31 Oct 2024
**Aqdot**, a young **UK-based company**, has completed all relevant regulatory and environmental hurdles and is now accelerating production and commercialisation of a novel macrocyclic chemical, **cucurbit\[n\]uril**, "**CB\[n**\]". Cucurbit\[n\]urils are extremely effective "supramolecular hosts": they non-covalently bind a wide range of chemical "guests...
Analysis and quality control of novel mixed cell population for therapeutic development
1 Jan 2024 to 30 Jun 2024
This project will focus on developing a critical quality control (QC) method that will allow manufacturers to test and ensure the quality of an immune therapy (called BioThymus). The BioThymus therapy is designed to treat a life-threatening disease in infants. Children born without a thymus gland (called complete DiGeorge Syndrome or cDGS) have a poorly f...
Indoor air quality measurements of formaldehyde using low cost sensors
1 Jan 2024 to 31 Mar 2024
Formaldehyde is a significant health risk, and International Agency for Research on Cancer (IARC) classifies formaldehyde as a human carcinogen. There are stringent formaldehyde exposure guidelines that exist for indoor air (80 ppb WHO) that can be even lower at the national level (e.g., France 8 ppb by 2023). People are exposed to formaldehyde from a var...
Mutated human oncogene recombinant nucleosomes as reference materials for liquid biopsy
1 Jan 2024 to 30 Jun 2024
Circulating tumour DNA (ctDNA) sequencing of plasma samples is becoming commonplace in clinical oncology practice and holds the promise to revolutionise cancer disease diagnosis and management. This promise is impeded by poor standardisation of ctDNA sequencing workflows, particularly in the pre-analytical phase. Limited control materials are currently av...
RADWIPES - Performance and Cleaning Efficacy
1 Jan 2024 to 31 Mar 2024
RADWIPES is the brand name of a cleaning product developed by MDCO Ltd. RADWIPES have been developed specifically for radiation decontamination activities associated with the decommissioning cleanup operations of legacy buildings on UK nuclear licensed sites, many of which, fall under the umbrella of the N.D.A. - Nuclear Decommissioning Authority. The ini...